VIVUS (VVUS) News Today → Kiss of death from Joe Biden (From Porter & Company) (Ad) Free VVUS Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share HeadlinesStock Analysis All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative January 8, 2024 | markets.businessinsider.comVIVUS Provides Update on Pipeline and Program MilestonesMay 25, 2023 | it.tmcnet.comMetaview announces Answers, the world's first conversational AI for the interview processOctober 2, 2022 | marketwatch.comWhy aren’t new drugs that can help you lose weight more widely used? - MarketWatchOctober 2, 2022 | morningstar.com'There's no way that patients are going to be able to afford that.' Why aren't new drugs that can help you lose weight more widely used? - MorningstarSeptember 23, 2022 | finance.yahoo.comErectile Dysfunction Drugs Market to Surpass Around USD 4079.9 Million by 2028, Says Brandessence Market Research - Yahoo FinanceSeptember 16, 2022 | streetinsider.comForm DEF 14A Catalent, Inc. For: Oct 27 - StreetInsider.comSeptember 9, 2022 | globenewswire.comObesity Management Market Expanding at an Impressive CAGR - GlobeNewswireAugust 26, 2022 | finance.yahoo.comGlobal Human Reproductive Technology Products and Markets Analysis Report 2022: Data from 2020-2021, Estimates for 2022, and CAGR Projections through 2027 - Yahoo FinanceAugust 26, 2022 | prnewswire.comGlobal Human Reproductive Technology Products and Markets Analysis Report 2022: Data from 2020-2021, Estimates for 2022, and CAGR Projections through 2027 - PR NewswireAugust 17, 2022 | stockhouse.com2022-08-15 | NDAQ:PTPI | Press Release | Petros Pharmaceuticals Inc. - StockhouseAugust 15, 2022 | streetinsider.comPetros Pharmaceuticals Reports Record Revenue and Gross Profit During Second Quarter 2022 - StreetInsider.comAugust 11, 2022 | finance.yahoo.comKaléo Announces Executive Appointments and New Government Business Unit - Yahoo FinanceAugust 5, 2022 | marketscreener.comIcahn Enterprises L P : Reports Second Quarter 2022 Financial Results - Form 8-K - Marketscreener.comAugust 2, 2022 | benzinga.comGlobal Cystic Fibrosis Market Report 2022-2030: CFTR Modulators Segment to Dominate the Market - BenzingaJuly 31, 2022 | businesswire.comGlobal Cystic Fibrosis Market Report 2022: Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts 2020-2030 - ResearchAndMarkets.com - Business WireJuly 26, 2022 | globenewswire.comGlobal Achondroplasia Market to Surpass US$ 1100.97 Million by 2030, Says Coherent Market Insights (CMI) - GlobeNewswireJuly 14, 2022 | fortune.comThe best stock investing strategy for 2022: Don’t buy the dip, buy the dividend - FortuneJuly 5, 2022 | finance.yahoo.comBioXcel Therapeutics Appoints Michael P. Miller to Board of Directors - Yahoo FinanceJuly 5, 2022 | streetinsider.comBioXcel Therapeutics Appoints Michael P. Miller to Board of Directors - StreetInsider.comJune 8, 2022 | benzinga.comOverweight Treatment Market estimated to surge ahead at a CAGR of 7.9% by the end of 2032 - Persistence M - BenzingaMay 16, 2022 | stockhouse.com2022-05-16 | NDAQ:PTPI | Press Release | Petros Pharmaceuticals Inc. - StockhouseMay 6, 2022 | fool.comIcahn Enterprises (IEP) Q1 2022 Earnings Call Transcript - The Motley FoolMay 3, 2022 | gurufocus.comPetros Pharmaceuticals to Pursue 505(B)(2) Pathway for H-100, Company's Novel Topical Investigational Treatment for Peyronie's Disease Which Impacts More Than 1 in 10 Men in the US - GuruFocus.comMay 3, 2022 | globenewswire.comPetros Pharmaceuticals to Pursue 505(B)(2) Pathway for H-100, Company's Novel Topical Investigational Treatment for Peyronie's Disease Which Impacts More Than 1 in 10 Men in the US - GlobeNewswireApril 27, 2022 | gurufocus.comPetros Pharmaceuticals, Inc. Engages Massachusetts General Hospital in a Sponsored Research Agreement for Tissue-Specific Oxygenation Sensor Technology - GuruFocus.comApril 26, 2022 | finance.yahoo.comPetros Pharmaceuticals, Inc. Engages Massachusetts General Hospital in a Sponsored Research Agreement for Tissue-Specific Oxygenation Sensor Technology - Yahoo FinanceApril 19, 2022 | globenewswire.comPetros Pharmaceuticals Announces Positive Results of Over-the-Counter (OTC) Label Comprehension Study for Erectile Dysfunction Drug STENDRA (avanafil) - GlobeNewswireApril 5, 2022 | prnewswire.comDiet Pills Market Size Worth $2.27Bn, Globally, by 2028 at 10.4% CAGR - Exclusive Report by The Insight Partners - PR NewswireApril 1, 2022 | businesswire.comGlobal Obesity Treatment Market Research Report to 2027 - Emerging Demand for Minimally Invasive Methods Presents Opportunities - ResearchAndMarkets.com - Business WireMarch 31, 2022 | marketscreener.comPETROS PHARMACEUTICALS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K) - Marketscreener.comMarch 30, 2022 | benzinga.comPhosphodiesterase Inhibitors Market: Industry Analysis and Opportunity Assessment 2028 - Benzinga - BenzingaMarch 23, 2022 | prnewswire.comErectile Dysfunction (ED) Drugs Market: 4.76% YOY Growth Rate in 2022 | By Product (oral drugs, topical drugs, and others) and Geography | Growth, Trends, and Forecasts (2022 - 2026) - PR NewswireMarch 16, 2022 | finance.yahoo.comDrugs For Erectile Dysfunction Global Market Report 2022 - Yahoo FinanceMarch 3, 2022 | marketscreener.comEquillium : Announces Appointment of Barbara Troupin to Board of Directors - Form 8-K - Marketscreener.comFebruary 26, 2022 | nasdaq.comWhy Zscaler Stock Plunged Today - NasdaqFebruary 25, 2022 | fool.comIcahn Enterprises (IEP) Q4 2021 Earnings Call Transcript - The Motley FoolFebruary 25, 2022 | seekingalpha.comIcahn Enterprises L.P. (IEP) CEO David Willetts on Q4 2021 Results - Earnings Call Transcript - Seeking AlphaFebruary 11, 2022 | finance.yahoo.comErectile Dysfunction Drugs Market size worth $ 2952 Million, Globally, by 2028 at -3.4% CAGR: Verified Market Research® - Yahoo FinanceJanuary 21, 2022 | marketscreener.comPETROS PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement (form 8-K) - marketscreener.comJanuary 19, 2022 | prnewswire.comPetros Pharmaceuticals Launches Two Self-Selection Studies for Erectile Dysfunction Drug STENDRA® (avanafil) - PRNewswireJanuary 4, 2022 | streetinsider.comAytu BioPharma Appoints Mark Oki as Chief Financial Officer - StreetInsider.comDecember 20, 2021 | streetinsider.comForm 424B3 Petros Pharmaceuticals, - StreetInsider.comDecember 10, 2021 | prnewswire.comPetros Pharmaceuticals Announces Positive Over-the-Counter (OTC) Label Comprehension Study Results for Erectile Dysfunction Drug STENDRA® (avanafil) - PRNewswireDecember 2, 2021 | streetinsider.comForm 424B5 Petros Pharmaceuticals, - StreetInsider.comNovember 15, 2021 | prnewswire.comPetros Pharmaceuticals Reports Third Quarter Financial Results and Provides Corporate Update - PRNewswireNovember 15, 2021 | marketscreener.comAnnouncement of Retirement of Judge Christopher Sontchi - marketscreener.comNovember 9, 2021 | prnewswire.comPetros Pharmaceuticals Expands Program for Novel Investigational Non-Invasive Treatment Formulation for Peyronie's Disease - PRNewswireNovember 8, 2021 | finance.yahoo.comObesity Treatment Market Research Report by Drugs, by Surgery & Devices, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19 - Yahoo FinanceNovember 3, 2021 | streetinsider.comEsperion Announces the Appointment of Seth HZ Fischer to its Board of Directors - StreetInsider.comNovember 3, 2021 | fool.comIcahn Enterprises (IEP) Q3 2021 Earnings Call Transcript - Motley Fool Get VIVUS News Delivered to You Automatically Sign up to receive the latest news and ratings for VVUS and its competitors with MarketBeat's FREE daily newsletter. Email Address ‘America’s Top Trader’ Who Predicted the Biggest Financial Events of The Last 30 Years, Issues New Warning… (Ad)Eric Fry has called every major market-event of the last 30 years... Also, recommending 41 stocks – with EACH one surging for 1,000%+ returns... Eric is releasing his biggest WARNING of 2024 VVUS Media Mentions By Week VVUS Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VVUS News Sentiment▼0.000.79▲Average Medical News Sentiment VVUS News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VVUS Articles This Week▼00▲VVUS Articles Average Week Get VIVUS News Delivered to You Automatically Sign up to receive the latest news and ratings for VVUS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Cumberland Pharmaceuticals News Today Eli Lilly and Company News Today Johnson & Johnson News Today Merck & Co., Inc. News Today AbbVie News Today Pfizer News Today Bristol-Myers Squibb News Today Zoetis News Today Royalty Pharma News Today Jazz Pharmaceuticals News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VVUS) was last updated on 6/1/2024 by MarketBeat.com Staff From Our PartnersThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss RatingsThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaBiden Nomination CANCELED?The Freeport SocietyMAJOR BUY SIGNAL: Move Fast, Washington/Pelosi/Mill…AltimetryUnlock Explosive Gains with This Defense StockBehind the MarketsMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin Pro Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VIVUS, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
